Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WPOIO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-Human CD33 BETd ADCs
|
|||||
| Synonyms |
Anti-Human CD33 BETd ADCs
Click to Show/Hide
|
|||||
| Organization |
AbbVie Inc., North Chicago, IL (US)
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
BETd drug
|
Payload Info | ||||
| Linker Name |
US20250000993A1 ADC Linker
|
Linker Info | ||||
| Conjugate Type |
site-specific conjugation
|
|||||
| Combination Type |
LD1
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | < 0.005 nM | |||
| Method Description |
Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb1-LD2
|
||||
| In Vitro Model | Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia | AML2 cells | CVCL_1619 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.005 nM
|
|||
| Method Description |
Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb1-LD2
|
||||
| In Vitro Model | Adult acute myeloid leukemia | MOLM-13 cells | CVCL_2119 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.005 nM
|
|||
| Method Description |
Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb1-LD2
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | < 0.005 nM | |||
| Method Description |
Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb1-LD3
|
||||
| In Vitro Model | Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia | AML2 cells | CVCL_1619 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.005 nM
|
|||
| Method Description |
Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb1-LD3
|
||||
| In Vitro Model | Adult acute myeloid leukemia | MOLM-13 cells | CVCL_2119 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | < 0.005 nM | |||
| Method Description |
Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb1-LD3
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.039 nM
|
|||
| Method Description |
Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb1-LD2
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP1 cells | CVCL_0006 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.073 nM
|
|||
| Method Description |
Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb1-LD3
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP1 cells | CVCL_0006 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
9.29 nM
|
|||
| Method Description |
Proliferation of AML cell lines in MV411 following treatment with ADCs, EC50 in mAb3-LD3
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
12.29 nM
|
|||
| Method Description |
Proliferation of AML cell lines in AML2 following treatment with ADCs, EC50 in mAb3-LD3
|
||||
| In Vitro Model | Adult acute myeloid leukemia, Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4, Acute myeloid leukemia | AML2 cells | CVCL_1619 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
14.38 nM
|
|||
| Method Description |
Proliferation of AML cell lines in MOLM13 following treatment with ADCs, EC50 in mAb3-LD3
|
||||
| In Vitro Model | Adult acute myeloid leukemia | MOLM-13 cells | CVCL_2119 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
20.27 nM
|
|||
| Method Description |
Proliferation of AML cell lines in THP1 following treatment with ADCs, EC50 in mAb3-LD3
|
||||
| In Vitro Model | Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia | THP1 cells | CVCL_0006 | ||